GO:0071501 cellular response to sterol depletion: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071501 describes how a cell changes its state or activity when sterols become scarce, including changes in gene expression, enzyme production, secretion and movement.
• The best-characterized sterol-depletion response is the SREBP2-SCAP-INSIG axis, which senses ER sterol levels and controls de novo cholesterol biosynthesis and uptake.
• Sterol depletion is not only a metabolic event; it reshapes immune signaling, inflammasome activity and inflammatory gene programs in macrophages and other myeloid cells.
• Cancer cells can hijack sterol-depletion responses to sustain proliferation, ribosome biogenesis and receptor tyrosine kinase signaling.
• Sterol intermediates such as desmosterol act as signaling molecules that suppress inflammasome activation, linking sterol flux to vascular inflammation.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect which sterol-responsive genes are causal rather than correlative.
Description
Cellular response to sterol depletion (GO:0071501) is the biological process by which a cell changes its state or activity in response to a stimulus indicating deprivation of sterols. Sterols are a group of steroids characterized by one or more hydroxyl groups and a hydrocarbon side-chain, and they are essential for membrane organization, lipid raft formation, hormone synthesis and cell signaling. When sterol availability falls, cells must rapidly reprogram transcription, lipid uptake, biosynthesis and secretory pathways to preserve membrane function and viability. This term therefore captures a stress-adaptive program that sits at the intersection of metabolism, membrane biology and signal transduction. Researchers study GO:0071501 because sterol depletion is a common feature of statin therapy, dietary lipid perturbation, tumor microenvironment remodeling and inflammatory disease. In cancer, sterol-depleted or cholesterol-auxotrophic states can drive immunosuppressive reprogramming and sustain oncogenic signaling through LRRC8A-caveolin-1 and KRAS/EGFR pathways. In the liver, hepatocytes respond to sterol depletion by enhancing de novo cholesterol biosynthesis to support regeneration, while Kupffer cells dictate hepatic responses to atherogenic dyslipidemia. In macrophages, sterol intermediates such as desmosterol suppress inflammasome activation, revealing that the sterol-depletion response is also an immune-regulatory node. Because the response is multi-layered, publication-grade studies require precise perturbation of sterol-sensing genes and quantitative readouts of transcription, lipid flux and signaling. This article summarizes the QuickGO definition, the core molecular machinery, the key genes, disease links and the CRISPR-based methods used to interrogate GO:0071501.
cellular response to sterol depletion At A Glance
| GO ID | GO:0071501 |
|---|---|
| GO term | cellular response to sterol depletion |
| Ontology | biological_process |
| Synonym | cellular sterol depletion response |
| Major function | Reprogramming of cellular state and activity, including gene expression, enzyme production, secretion and movement, in response to sterol deprivation |
| Definition source | QuickGO definition: any process that results in a change in state or activity of a cell as a result of a stimulus indicating deprivation of sterols |
| Key sensing module | SREBP2-SCAP-INSIG sterol-sensing complex in the endoplasmic reticulum |
| Representative stimuli | Statin treatment, sterol-like drugs, dietary lipid perturbation, tumor microenvironment lipid stress |
| Representative readouts | SREBP2 nuclear translocation, cholesterol biosynthesis gene expression, inflammasome activation, receptor tyrosine kinase signaling |
What Is GO:0071501?
In our own words, GO:0071501 (cellular response to sterol depletion) is any process that results in a change in state or activity of a cell as a result of a stimulus indicating deprivation of sterols. The response can include changes in movement, secretion, enzyme production and gene expression, and it is triggered when sterol levels fall below the cell's homeostatic set point. Sterols are steroids with one or more hydroxyl groups and a hydrocarbon side-chain, and their depletion is sensed by membrane-embedded and ER-resident proteins that convert the lipid signal into transcriptional and post-transcriptional outputs. The synonym cellular sterol depletion response is used interchangeably.
Why Is cellular response to sterol depletion Important in Cell Biology?
GO:0071501 matters because sterol depletion is a physiologically and pharmacologically common state that forces cells to choose between adaptation and death. The response determines whether cells upregulate de novo cholesterol biosynthesis, import exogenous sterols, remodel membranes or activate inflammatory and stress programs. Clinically, this process is central to statin pharmacology, atherosclerosis, prostate cancer cell death and pancreatic ductal adenocarcinoma growth, and it shapes antitumor immunity through cholesterol-dependent reprogramming of myeloid cells. Understanding the causal genes in this response is therefore essential for target discovery and for predicting drug response.
• Defines how cells adapt transcriptionally and metabolically when sterols are scarce, a state induced by statins and sterol-like drugs.
• Controls de novo cholesterol biosynthesis and liver regeneration through hepatocyte metabolic remodeling.
• Links sterol sensing to inflammasome suppression and vascular inflammation via desmosterol.
• Drives immunosuppressive reprogramming of intratumoral myeloid cells through cancer cell-intrinsic XBP1 and cholesterol production.
• Sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma via a cholesterol-dependent LRRC8A-caveolin-1 axis.
• Shapes hepatic responses to atherogenic dyslipidemic insult through Kupffer cell-dependent mechanisms.
• Provides a mechanistic basis for combination strategies that potentiate statin-triggered cancer cell death by inhibiting SREBP2 nuclear translocation.
• Connects lipid metabolism to aging-related signaling such as mTORC1 through YTHDF1-dependent regulation.
• Is relevant to skin inflammation and T(FH) differentiation in atopic dermatitis models.
• Offers a tractable CRISPR target set for metabolic, oncologic and immunologic research.
What Happens During cellular response to sterol depletion?
Sterol sensing at the endoplasmic reticulum
In simple terms: The cell first checks how much sterol is present in its internal membranes.
The canonical trigger of GO:0071501 is a drop in endoplasmic reticulum (ER) sterol levels, which is sensed by the SREBP2-SCAP-INSIG module. When sterols are abundant, SCAP binds cholesterol and retains SREBP2 in the ER; when sterols are depleted, this retention is relieved and SREBP2 is transported to the Golgi for proteolytic activation. Sterol-like drugs can potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation, demonstrating that this sensing step is pharmacologically actionable. In hepatocytes, SLC13A2 promotes metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis, placing ER sterol sensing upstream of regenerative programs.
Transcriptional reprogramming of sterol biosynthesis and uptake
In simple terms: Once the cell knows sterols are low, it switches on genes that make and import cholesterol.
Activated SREBP2 translocates to the nucleus and induces genes of the mevalonate and cholesterol biosynthesis pathways as well as LDL receptor-mediated uptake, thereby restoring sterol supply. This transcriptional arm is a defining output of GO:0071501 and is commonly measured by expression of HMGCR, HMGCS1, LDLR, SQLE and MVD. In liver regeneration models, enhanced de novo cholesterol biosynthesis is required for hepatocyte proliferation, showing that the transcriptional response is not merely homeostatic but also regenerative. In pancreatic ductal adenocarcinoma, cholesterol dependency sustains KRAS/EGFR signaling and ribosome biogenesis, indicating that the transcriptional response can be co-opted for oncogenic growth.
Membrane and lipid raft remodeling
In simple terms: The cell changes the physical properties of its membranes to cope with less sterol.
Sterols are structural components of plasma and organelle membranes, and their depletion alters membrane fluidity, raft integrity and the localization of signaling proteins. A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling and ribosome biogenesis in pancreatic ductal adenocarcinoma, illustrating how sterol availability controls membrane-proximal signaling platforms. In macrophages, the sterol intermediate desmosterol suppresses inflammasome activation and protects against vascular inflammation, showing that specific sterol species within membranes act as signaling molecules rather than passive lipids. These membrane changes are part of the cellular response to sterol depletion and can be monitored by imaging and lipidomics.
Inflammatory and immune signaling outputs
In simple terms: Sterol depletion also changes how immune cells talk to each other.
Sterol depletion and cholesterol production are linked to immune reprogramming. Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production, connecting sterol metabolism to tumor immune evasion. Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis, defining an anti-inflammatory arm of the sterol-depletion response. In skin, Langerhans cells have a dual function in TSLP-promoted T(FH) differentiation in mouse atopic dermatitis, indicating that sterol- and lipid-responsive immune circuits operate in barrier tissues. Kupffer cells dictate hepatic responses to atherogenic dyslipidemic insult, further linking sterol stress to liver immune cell crosstalk.
Integration with growth and aging signaling
In simple terms: Sterol stress is wired into the cell's growth and aging decisions.
The sterol-depletion response intersects with mTORC1 and aging-related pathways. YTHDF1 differentiates the contributing roles of mTORC1 in aging, providing a mechanistic link between nutrient/lipid stress signaling and longevity programs. Because mTORC1 is a central growth regulator, its crosstalk with sterol sensing helps explain why sterol-depleted cancer cells can either arrest or adapt to sustain proliferation. This integration means that GO:0071501 should be interpreted as part of a broader nutrient-stress network rather than an isolated lipid pathway.
Key Genes Involved in GO:0071501 cellular response to sterol depletion
The following genes and proteins are experimentally implicated in sterol sensing, sterol biosynthesis, sterol-dependent signaling and the immune outputs of cellular response to sterol depletion.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SREBP2 (SREBF2) | Master transcription factor of cholesterol biosynthesis and uptake; nuclear translocation is inhibited by sterol-like drugs | Central readout and drug target in sterol-depletion studies |
| SCAP (SCAP) | ER sterol sensor that retains SREBP2 when sterols are abundant | Knockout/point-mutation models define sensing thresholds |
| INSIG1/INSIG2 | ER retention proteins that block SREBP2 processing under sterol-replete conditions | Loss-of-function causes constitutive sterol response |
| HMGCR | Rate-limiting enzyme of the mevalonate pathway and statin target | Expression and activity readout of sterol depletion |
| HMGCS1 | Mevalonate pathway enzyme induced by SREBP2 | Transcriptional marker of the sterol-depletion response |
| LDLR | Mediates uptake of exogenous cholesterol | Functional readout of sterol demand |
| SQLE | Squalene epoxidase in cholesterol biosynthesis | Target for sterol-pathway perturbation |
| MVD | Mevalonate diphosphate decarboxylase in sterol biosynthesis | Supports de novo cholesterol flux in regeneration models |
| SLC13A2 | Promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis | Knockout models test regeneration dependence on sterol synthesis |
| XBP1 | Cancer cell-intrinsic driver of cholesterol production and immunosuppressive myeloid reprogramming | Links sterol metabolism to tumor immunity |
| LRRC8A | Cholesterol-dependent component sustaining KRAS/EGFR signaling and ribosome biogenesis | Membrane-proximal node in pancreatic cancer |
| CAV1 (caveolin-1) | Cholesterol-binding scaffold in the LRRC8A-caveolin-1 axis | Membrane raft and signaling readout |
| KRAS | Oncogenic GTPase whose signaling depends on cholesterol availability | Model for sterol-dependent oncogenic signaling |
| EGFR | Receptor tyrosine kinase sustained by cholesterol-dependent signaling | Readout of membrane signaling under sterol stress |
| DHCR24 | Enzyme in cholesterol biosynthesis and desmosterol metabolism | Links sterol intermediates to inflammasome control |
| YTHDF1 | m6A reader that differentiates mTORC1 contributions to aging | Connects sterol stress to aging and translation control |
| TSLP | Cytokine promoting T(FH) differentiation via Langerhans cells in atopic dermatitis | Immune-context link to lipid-responsive skin inflammation |
| Kupffer cell markers (e.g., CLEC4F) | Hepatic macrophage population dictating responses to atherogenic dyslipidemia | Model for liver immune-metabolic crosstalk |
How Is cellular response to sterol depletion Regulated?
Cellular response to sterol depletion is regulated at multiple levels. The primary switch is the ER sterol-sensing SREBP2-SCAP-INSIG module, in which sterol binding controls SREBP2 retention and proteolytic activation. Pharmacological inhibition of SREBP2 nuclear translocation by sterol-like drugs can potentiate statin-triggered prostate cancer cell death, showing that this step is a regulatory node. Downstream, the response is modulated by growth and nutrient signaling; mTORC1 crosstalk with YTHDF1 influences aging-related outputs, indicating that sterol stress is integrated with translation and longevity pathways. In immune cells, sterol intermediates such as desmosterol regulate inflammasome activation, providing a feedback layer that restrains inflammation during sterol flux. In the liver, SLC13A2-dependent enhancement of de novo cholesterol biosynthesis regulates regenerative capacity, and Kupffer cells shape hepatic responses to atherogenic dyslipidemic insult. Finally, cancer cell-intrinsic XBP1 promotes cholesterol production and immunosuppressive reprogramming, illustrating cell-type-specific regulation of the sterol-depletion response.
cellular response to sterol depletion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| XBP1 | Tumor immunosuppression via cholesterol production | Cancer cell knockout and syngeneic tumor models |
| LRRC8A / CAV1 | Pancreatic ductal adenocarcinoma growth and KRAS/EGFR signaling | Knockout and cholesterol-dependence assays in PDAC lines |
| SREBP2 | Prostate cancer cell death potentiated by statins and sterol-like drugs | Point-mutation of nuclear translocation motif and drug-response assays |
| SLC13A2 | Liver regeneration and hepatocyte metabolic remodeling | Hepatocyte knockout and partial hepatectomy models |
| DHCR24 / desmosterol pathway | Atherosclerosis and vascular inflammation | Macrophage knockout and inflammasome activation assays |
Cancer metabolism and therapy resistance
Sterol depletion responses are co-opted by tumors to sustain growth and evade therapy. Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production, linking sterol metabolism to immune evasion. In pancreatic ductal adenocarcinoma, a cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth, making sterol availability a vulnerability. In prostate cancer, sterol-like drugs potentiate statin-triggered cell death by inhibiting SREBP2 nuclear translocation, showing that the sterol-sensing step can be therapeutically exploited. These findings position GO:0071501 as a central node in metabolic oncology.
Atherosclerosis and vascular inflammation
Sterol depletion and sterol intermediates directly influence vascular inflammation. Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis, defining an anti-inflammatory sterol-sensing output. Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult, connecting liver macrophage biology to systemic lipid stress. Together, these studies show that the cellular response to sterol depletion is a determinant of atherosclerotic plaque biology and hepatic lipid handling.
Liver regeneration and metabolic liver disease
Hepatocytes mount a robust sterol-depletion response to support regeneration. SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis, demonstrating that sterol synthesis is required for proliferative recovery. Because Kupffer cells shape hepatic responses to atherogenic dyslipidemia, the liver is a key tissue for studying GO:0071501 in both regenerative and inflammatory contexts.
Inflammatory skin disease and immune differentiation
Lipid- and sterol-responsive immune circuits operate in barrier tissues. Langerhans cells have a dual function in skin TSLP-promoted T(FH) differentiation in mouse atopic dermatitis, indicating that sterol- and lipid-linked signaling influences cutaneous immunity. This context expands the disease relevance of GO:0071501 beyond metabolic and cardiovascular disease into allergic inflammation.
From cellular response to sterol depletion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is SREBP2 nuclear translocation required for sterol-depletion gene expression? | Point-mutation knock-in of SREBP2 cleavage/nuclear localization residues |
| Does loss of SCAP or INSIG alter the sterol-depletion transcriptional program? | CRISPR knockout of SCAP or INSIG1/INSIG2 with RNA-seq readout |
| Is SLC13A2-dependent cholesterol biosynthesis required for liver regeneration? | Hepatocyte-specific knockout and partial hepatectomy |
| Does XBP1-driven cholesterol production reprogram intratumoral myeloid cells? | Cancer cell knockout plus myeloid profiling in syngeneic tumors |
| Is the LRRC8A-caveolin-1 axis cholesterol-dependent in PDAC? | Knockout and cholesterol-depletion/rescue in PDAC models |
| Can sterol intermediates such as desmosterol suppress inflammasome activation? | Macrophage overexpression or knock-in of desmosterol-producing enzymes |
How to Study the cellular response to sterol depletion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptional changes after sterol depletion | Define SREBP2 target programs and XBP1-dependent signatures |
| Quantitative PCR | Expression of HMGCR, HMGCS1, LDLR, SQLE, MVD | Rapid validation of sterol-depletion response |
| Lipidomics (LC-MS) | Cholesterol and sterol intermediate abundance | Confirm sterol depletion and desmosterol levels |
| Isotope tracing | De novo cholesterol biosynthesis flux | Measure mevalonate pathway activity in liver and cancer models |
| Immunoblotting / imaging | SREBP2 nuclear translocation and SCAP-INSIG interaction | Assess sterol-sensing step and drug effects |
| Inflammasome activation assay | IL-1beta processing and caspase-1 activity | Test desmosterol-mediated suppression in macrophages |
| CRISPR knockout screening | Gene essentiality under sterol depletion | Identify causal sterol-response genes |
| Co-immunoprecipitation | LRRC8A-caveolin-1 and signaling complexes | Probe cholesterol-dependent membrane signaling |
Transcriptional profiling of the sterol-depletion response
RNA-seq after statin treatment, sterol-like drug exposure or CRISPR perturbation of SREBP2-SCAP-INSIG is the standard approach to define the gene expression arm of GO:0071501. Quantitative PCR for HMGCR, HMGCS1, LDLR, SQLE and MVD provides a rapid readout of SREBP2 target activation. In cancer models, RNA-seq can reveal XBP1-dependent cholesterol programs and immunosuppressive signatures.
Lipidomics and sterol flux measurement
Mass spectrometry-based lipidomics quantifies cholesterol, desmosterol and other sterol intermediates to determine whether cells are truly sterol-depleted or have adapted. Isotope tracing with labeled acetate or mevalonate measures de novo cholesterol biosynthesis, which is especially informative in hepatocyte regeneration and cancer models. These methods complement transcriptional data and are essential for publication-grade claims about sterol depletion.
Protein localization and signaling assays
Immunoblotting and imaging of SREBP2 nuclear translocation, SCAP-INSIG interaction and Golgi processing define the sensing step. Membrane raft integrity and cholesterol-dependent signaling can be assessed by caveolin-1 co-localization and receptor tyrosine kinase phosphorylation, as shown for the LRRC8A-caveolin-1 axis in pancreatic cancer. Inflammasome activation assays in macrophages measure the immune output of sterol intermediates such as desmosterol.
CRISPR perturbation and functional genomics
Pooled CRISPR knockout screens targeting sterol-sensing and biosynthesis genes can identify which components are required for survival or growth under sterol depletion. Focused validation with single-gene knockouts, point mutations and rescue constructs distinguishes causal from correlative hits. Combining CRISPR screening with RNA-seq and lipidomics provides a multi-omic view of GO:0071501.
How CRISPR Can Be Used to Study GO:0071501 cellular response to sterol depletion
Knockout
CRISPR knockout is used to remove sterol-sensing or biosynthesis genes such as SCAP, INSIG1/INSIG2, SLC13A2, XBP1, LRRC8A and CAV1, then measure transcriptional, lipidomic and signaling outputs of GO:0071501. Knockout of SLC13A2 in hepatocytes tests whether de novo cholesterol biosynthesis is required for liver regeneration. Knockout of XBP1 in cancer cells tests whether cholesterol production drives immunosuppressive myeloid reprogramming. These models establish necessity but should be paired with rescue experiments to exclude off-target effects.
Point Mutation
Point-mutation knock-in can dissect specific residues required for sterol sensing, SREBP2 cleavage or nuclear translocation. For example, mutating the SREBP2 nuclear localization or cleavage site can test whether nuclear translocation is the critical step inhibited by sterol-like drugs in prostate cancer cells. Point mutations in SCAP sterol-binding residues can define the threshold for ER retention and activation. These models are ideal when a domain-specific function must be separated from total loss of protein.
Knock-in
Knock-in of tagged alleles (e.g., HA- or GFP-tagged SREBP2, SCAP or INSIG) enables live-cell imaging and proximity proteomics of the sterol-sensing complex. Knock-in of reporter cassettes driven by sterol-responsive promoters allows quantitative monitoring of the transcriptional response in real time. In immune cells, knock-in of desmosterol-producing enzymes can test whether specific sterol intermediates suppress inflammasome activation. These approaches preserve endogenous regulation and are preferred for mechanistic claims.
Overexpression
Overexpression of SREBP2, XBP1, LRRC8A or caveolin-1 can test sufficiency of individual nodes in driving sterol-depletion outputs such as cholesterol production, KRAS/EGFR signaling or immunosuppressive reprogramming. Overexpression of DHCR24 or desmosterol-synthesizing enzymes can elevate sterol intermediates and test inflammasome suppression. Overexpression models are useful for gain-of-function screens but should be interpreted with attention to non-physiological protein levels.
How EDITGENE Supports cellular response to sterol depletion Research
Researchers studying cellular response to sterol depletion-related genes often need to determine whether a candidate gene is causally involved in sterol sensing, biosynthesis, membrane signaling or immune reprogramming, rather than merely correlated with the phenotype. EDITGENE provides publication-grade CRISPR models and screening services that allow precise perturbation of SREBP2-SCAP-INSIG components, sterol biosynthesis enzymes and downstream effectors in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for cellular response to sterol depletion research.
Frequently Asked Questions About cellular response to sterol depletion
What is GO:0071501 cellular response to sterol depletion?
GO:0071501 is a biological process describing any change in a cell's state or activity, such as movement, secretion, enzyme production or gene expression, caused by deprivation of sterols.
What genes are involved in cellular response to sterol depletion?
Key genes include SREBP2, SCAP, INSIG1/INSIG2, HMGCR, HMGCS1, LDLR, SQLE, MVD, SLC13A2, XBP1, LRRC8A, CAV1, KRAS, EGFR, DHCR24 and YTHDF1.
How does the cell sense sterol depletion?
The ER-resident SREBP2-SCAP-INSIG module senses falling sterol levels and releases SREBP2 for Golgi processing and nuclear translocation.
Why is sterol depletion important in cancer?
Cancer cells can use sterol-depletion responses to sustain KRAS/EGFR signaling, ribosome biogenesis, cholesterol production and immunosuppressive reprogramming.
What is the role of SREBP2 in sterol depletion?
SREBP2 is the master transcription factor that induces cholesterol biosynthesis and uptake genes when sterols are low, and its nuclear translocation can be inhibited by sterol-like drugs.
How is cellular response to sterol depletion studied?
Common methods include RNA-seq, quantitative PCR of SREBP2 targets, lipidomics, isotope tracing, imaging of SREBP2 localization and CRISPR knockout screens.
Does sterol depletion affect inflammation?
Yes, sterol intermediates such as desmosterol suppress macrophage inflammasome activation and protect against vascular inflammation and atherosclerosis.
What is the link between sterol depletion and liver regeneration?
SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis, and Kupffer cells shape hepatic responses to atherogenic dyslipidemia.
Can CRISPR be used to study sterol depletion responses?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models are widely used to test causal roles of sterol-sensing and biosynthesis genes.
What diseases are linked to cellular response to sterol depletion?
Links include cancer metabolism, atherosclerosis, vascular inflammation, liver regeneration disorders and inflammatory skin disease such as atopic dermatitis.
Conclusion
Cellular response to sterol depletion (GO:0071501) is a multi-layered adaptive program that converts a lipid shortage into transcriptional, metabolic, membrane and immune changes. The SREBP2-SCAP-INSIG sensing module, sterol biosynthesis enzymes and downstream effectors such as XBP1, LRRC8A, caveolin-1 and desmosterol pathways define the core machinery. Because this response influences cancer growth, atherosclerosis, liver regeneration and inflammation, it is a high-value target space for mechanistic and translational research. Publication-grade studies of GO:0071501 require precise genetic perturbation and orthogonal readouts. CRISPR knockout, point-mutation, knock-in and overexpression models, combined with RNA-seq, lipidomics and screening, provide the causal evidence needed to move from correlation to mechanism. EDITGENE supports these workflows with validated cell models and bioinformatics, helping researchers interrogate sterol-depletion biology with confidence.
References
- 1. Yang Z et al.. 2022. Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production.. Cell Metab 34(12):2018-2035.e8 PMID: 36351432
- 2. Xu C et al.. 2025. YTHDF1 differentiates the contributing roles of mTORC1 in aging.. Mol Cell 85(11):2194-2210.e8 PMID: 40441158
- 3. Marschall P et al.. 2021. Dual function of Langerhans cells in skin TSLP-promoted T(FH) differentiation in mouse atopic dermatitis.. J Allergy Clin Immunol 147(5):1778-1794 PMID: 33068561
- 4. Ye Q et al.. 2026. A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma.. Oncogene 45(30):3083-3101 PMID: 42321533
- 5. Shi L et al.. 2025. SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis.. EMBO J 44(5):1442-1463 PMID: 39824985
- 6. Di Nunzio G et al.. 2024. Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult.. Nat Cardiovasc Res 3(3):356-371 PMID: 39196121
- 7. Zhang X et al.. 2021. Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis.. Proc Natl Acad Sci U S A 118(47) PMID: 34782454
- 8. Dos Santos DZ et al.. 2024. Sterol-like drugs potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation.. Biomed Pharmacother 177:116934 PMID: 38889639
